Placebo in combination with Cytarabine Injection + Liposomal Annamycin Injection in combination with Cytarabine Injection + Liposomal Annamycin Injection in combination with Cytarabine Injection + Liposomal Annamycin for Injection in combination with Cytarabine Injection.
Phase 2/3Recruiting 0 watching 0 views this week⚡ Active
57
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Acute Myeloid Leukaemia (AML)
Conditions
Acute Myeloid Leukaemia (AML)
Trial Timeline
Mar 12, 2025 → Aug 1, 2030
NCT ID
NCT06788756About Placebo in combination with Cytarabine Injection + Liposomal Annamycin Injection in combination with Cytarabine Injection + Liposomal Annamycin Injection in combination with Cytarabine Injection + Liposomal Annamycin for Injection in combination with Cytarabine Injection.
Placebo in combination with Cytarabine Injection + Liposomal Annamycin Injection in combination with Cytarabine Injection + Liposomal Annamycin Injection in combination with Cytarabine Injection + Liposomal Annamycin for Injection in combination with Cytarabine Injection. is a phase 2/3 stage product being developed by Moleculin Biotech for Acute Myeloid Leukaemia (AML). The current trial status is recruiting. This product is registered under clinical trial identifier NCT06788756. Target conditions include Acute Myeloid Leukaemia (AML).
Hype Score Breakdown
Clinical
22
Activity
15
Company
2
Novelty
7
Community
8
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06788756 | Phase 2/3 | Recruiting |
Competing Products
20 competing products in Acute Myeloid Leukaemia (AML)